The effects of anti-asthma drugs on mediator release from cultured human mast cells

Clinical and Experimental Allergy

Volumn 28, Issue 10, 1998, Pages 1228-1236

  Shichijo, M ^a   Inagaki, N ^a   Nakai, N ^a   Kimata, M ^a   Nakahata, T ^b   Serizawa, I ^c   Iikura, Y ^d   Saito, H ^e   Nagai, H ^a  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c KIRIN BREWERY CO LTD   (Japan)

^d SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

Author keywords

Anti asthma drugs; Cultured mast cells; Histamine; Leukotriene; Prostaglandin D2

Indexed keywords

2 CYCLOPENTYL 2 [4 (2 QUINOLINYLMETHOXY)PHENYL]ACETIC ACID; AZELASTINE; CILOSTAZOL; CLENBUTEROL; CROMOGLYCATE DISODIUM; ISOPRENALINE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; ROLIPRAM; SALBUTAMOL; THEOPHYLLINE;

ALLERGY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BETA ADRENERGIC STIMULATION; CELL CULTURE; CONCENTRATION RESPONSE; DRUG EFFECT; HISTAMINE RELEASE; HUMAN; HUMAN CELL; IMMUNOREGULATION; MAST CELL; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROSTAGLANDIN SYNTHESIS INHIBITION;

ANTI-ASTHMATIC AGENTS; CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENZYME-LINKED IMMUNOSORBENT ASSAY; HISTAMINE RELEASE; HUMANS; IMMUNOENZYME TECHNIQUES; INFLAMMATION MEDIATORS; LEUKOTRIENES; MAST CELLS; PROSTAGLANDIN D2;

EID: 0032466569     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2222.1998.00394.x     Document Type: Article

References (41)

1. Saito H, Ebisawa M, Sakaguchi N et al. Characterization of cord-blood-derived human mast cells cultured in the presence of steel factor and interleukin-6. Int Arch Alleygy Immunol 1995; 107:63-5.
2. Saito H, Ebisawa M, Tachimoto H et al. Selective growth of human mast cells induced by steel factor, IL-6, and prostaglandin E2 from cord blood mononuclear cells. J Immunol 1996; 157:343-50.
3. Obata T, Nagakura T, Kanbe M et al. IgE-anti-IgE-induced prostaglandin D2 release from cultured human mast cells. Biochem Biophys Res Commun 1996; 225:1015-20.
4. Yanagida M, Fukamachi H, Ohgami K et al. Effects of T- helper 2-type cytokines, interleukin-3 (IL-3), IL-4, IL-5, and IL-6 on the survival of cultured human mast cells. Blood 1995; 86:3705-14.
5. Igarashi Y, Kurosawa M, Ishikawa O et al. Characteristics of histamine release from cultured human mast cells. Clin Exp Allergy 1996; 26:597-602.
6. Irani AA, Schecter NM, Craig SS, DeBlois G, Schwartz LB. Two types of human mast cells that have distinct neutral protease compositions. Proc Natl Acad Sci USA 1986; 83:4464-8.
7. Church MK, Hiroi J. Inhibition of IgE-dependent histamine release from human dispersed lung mast cells by anti-allergic drugs and salbutamol. Br J Pharmacol 1987; 90:421-9.
8. Torphy TJ, Undem BJ. Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax 1991; 46:512-23.
9. Müller-Peddinghaus R, Kohlsdorfer C, Theisen-Popp P et al. BAY x 1005, a new inhibitor of leukotriene synthesis: In vivo inflammation pharmacology and pharmacokinetics. J Pharmacol Exp Ther 1993; 267:51-7.
10. Futaki N, Yoshikawa K, Hamasaki Y et al. NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen Pharmac 1993; 24:105-10.
11. Craig SS, DeBlois G, Schwartz LB. Mast cells in human keloid, small intestine, and lung by an immunoperoxydase technique using a murine monoclonal antibody against tryptase. Am J Pathol 1986; 124:427-35.
12. Yamatodani A, Fukuda H, Wada H. High-performance liquid Chromatographic determination of plasma and brain histamine without previous purification of biological samples: Cation- exchange chromatography coupled with post-column derivatization fluorometry. J Chrom 1985; 344:115-23.
13. De Weck AL, Stadler BM, Urwyler A, Wehner HUU, Bühlmann RP. Cellular allergen stimulation test (CAST) -A new dimension in allergy diagnostics. Allergy Clin Immunol News 1993; 5:9-14.
14. Maclouf J, Grassi J, Pradelles P. Development of enzyme- immunoassay techniques for the measurement of eicosanoids. Prostaglandin and Lipid Metabolism in Radiation Injury 1987; 355-364.
15. Banner KH, Page CP, Anti-inflammatory effects of theophylline and selective phosphodiesterase inhibitors. Clin Exp Allergy 1996; 26 (S2):2-9.
16. Howell JBL, Altounyan REC. A double blind trial of disodium cromoglycate in the treatment of allergic bronchial asthma. Lancet 1967; 2:539-542.
17. Moran F, Bankier JDH, Boyd G. Disodium cromoglycate in the treatment of allergic bronchial asthma. Lancet 1968; 2:137-139.
18. Ollier S, Gould CA, Davies RJ. The effect of single and multiple dose therapy with azelastine on the immediate asthmatic response to allergy provocation testing. J Allergy Clin Immunol 1986; 78:358-64.
19. Thomson DS, Evans DP. Inhibition of immediate hypersensitivity reactions by disodium cromoglycate. Requirements for activity in two laboratory models. Clin Exp Immunol 1973; 13:537-44.
20. Orr TSC. Mode of action of disodium cromoglycate. Acta Allergologica Suppl. 1977; 13:329-27.
21. Fischer B, Schmutzler W. Inhibition by azelastine of the immunologically induced histamine release from isolated guinea pig mast cells. Arzneimittelforschung 1981; 31 (8 Part 2): 1193-5.
22. Chand N, Pillar J, Diamantis W, Sofia RD. Inhibition of IgE- mediated allergic histamine release from rat peritoneal mast cells by azelastine and selected antiallergic drugs. Agents Actions 1985; 16:318-22.
23. Butchers PR, Fullarton JR, Skidmore IF, Vardey CJ, Wheeldon A. A comparison of the anti-anaphylactic activities of salbutumol and disodium cromoglycate in rat, the rat mast cells and in human lung tissue. Br J Pharmacol 1979; 67:23- 32.
24. Church MK, Young KD. The characteristics of inhibition of histamine from human lung fragments by sodium cromoglycate, salbutamol and chlorpromazine. Br J Pharmacol 1983; 78:671-9.
25. Little MM, Wood DR, Casale TB. Azelastine inhibits stimulated histamine release from human lung tissue in vitro but doses not alter cyclic nucleotide content. Agents Actions 1989; 28:16-21.
26. Okayama Y, Benyon RC, Rees PH et al. Inhibition profiles of sodium cromoglycate and nedocromil sodium on mediator release from mast cells of human skin, lung, tonsil, adenoid and intestine. Clin Exp Allergy 1992; 22:401-9.
27. Sheard P, Blair AMJN. Disodium cromoglycate, activity in three in vitro models of the immediate hypersensitivity reaction in lung. Int Arch Allergy Appl Immunol 1970; 38:217-24.
28. Chand N, Diamantis W, Sofia RD. Antagonism of leukotrienes, calcium and other spasmogens by azelastine. Pharmacologist 1984; 26:152.
29. Diamantis W, Chand N, Harrison JE et al. Inhibition of release of SRS-A and its antagonism by azelastine (A), an H1 antagonist-antiallergic agent. Pharmacologist 1982; 24:200.
30. Peters SP, Schulman ES, Schleimer RP et al. Dispersed human lung mast cells. Pharmacologic aspects and comparison with human lung fragments. Am Rev Respir Dis 1982; 126:1034-9.
31. Young KD, Church MK. Passive anaphylaxis in human lung fragments as a model for testing anti-allergic drugs: its variability and constraints. Int Arch Allergy Appl Immunol 1983; 70:138-42.
32. Hughes JM, Seale JP, Temple DM. Effects of fenoterol on immunological release of leukotrienes and histamine from human lung in vitro. Selective antagonism by β-adrenoceptor antagonists. Eur J Pharmacol 1983; 95:239-45.
33. Peachell PT, MacGlashan DW, Lichtenstein LM, Schleimer RP. Regulation of human basophil and lung mast cell function by cyclic adcnosine monophosphate. J Immunol 1988; 140:571-9.
34. Undem BJ, Peachell PT, Lichtenstein LM. Isoprotenol-induced inhibition of immunoglobulin E-mediated release of histamine and arachidonic acid metabolites from the human lung mast cells. J Pharmacol Exp Ther 1988; 247:209-17.
35. Okayama Y, Church MK. Comparison of the modulatory effect of ketotifen, sodium cromoglycate, procaterol and salbutamol in human skin, lung and tonsil mast cells. Int Arch Allergy Immunol 1992; 97:216-25.
36. Pearce FL, Befus AD, Gauldie J, Bienenstock J. Effects of anti-allergic compounds on histamine secretion by isolated mast cells. J Immunol 1982; 128:2481-6.
37. Torphy TJ, Livi GP, Balcarek JM et al. Therapeutic potential of isozyme-selective phosphodiesterase inhibitors in the treatment of asthma. Adv Sec Messenger Phosphoprotein Res 1992; 25:289-305.
38. Louis RE, Radermecker MF. Substance P induced histamine release from human basophils, skin and lung fragments: effect of nedocromil sodium and theophylline. Int Arch Allergy Appl Immunol 1990; 92:329-33.
39. Louis R, Bury TH, Corhay JL, Radermecker M. LY 186655, a phosphodiesterase inhibitor, inhibits histamine release from human basophils, lung and skin fragments, Int J Immunopharmac 1992; 14:191-4.
40. Stevenson DD. Proposed mechanism of aspirin sensitivity reactions. J Allergy Clin Immunol 1987; 80:788-90.
41. Sladek K, Szczeklik A. Cysteinyl leukotrienes overproduction and mast cell activation in aspirin-provoked bronchospasm in asthma. Eur Repir J 1993; 6:391-9.